A double blind, placebo-controlled, dose ranging study in males over the age of 65, who have
a history of nocturia. The study will investigate pharmacodynamic outcomes (urine volumes and
osmolality, circulating coagulation factors and haemodynamics) and pharmacokinetics, of both
single and multiple oral doses of VA106483 at three dose levels, under conditions of
controlled hydration.